1. Home
  2. OPK vs AVLN Comparison

OPK vs AVLN Comparison

Compare OPK & AVLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo OPKO Health Inc.

OPK

OPKO Health Inc.

HOLD

Current Price

$1.34

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Logo Avalyn Pharma Inc. Common Stock

AVLN

Avalyn Pharma Inc. Common Stock

N/A

Current Price

$28.73

Market Cap

1.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
OPK
AVLN
Founded
2006
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.3B
IPO Year
2011
2026

Fundamental Metrics

Financial Performance
Metric
OPK
AVLN
Price
$1.34
$28.73
Analyst Decision
Hold
Analyst Count
3
0
Target Price
$1.60
N/A
AVG Volume (30 Days)
4.4M
258.9K
Earning Date
04-28-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$606,879,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$4.24
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.98
$24.90
52 Week High
$1.73
$33.32

Technical Indicators

Market Signals
Indicator
OPK
AVLN
Relative Strength Index (RSI) 50.42 43.91
Support Level $1.25 $26.68
Resistance Level $1.41 $29.59
Average True Range (ATR) 0.09 1.99
MACD 0.02 0.19
Stochastic Oscillator 30.74 61.44

Price Performance

Historical Comparison
OPK
AVLN

About OPK OPKO Health Inc.

OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.

About AVLN Avalyn Pharma Inc. Common Stock

Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.

Share on Social Networks: